Evidence map›Paper›PMID 42030147›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Design principles of the cytotoxic CD8

Obinna A Ukogu, Zachary Montague, Grégoire Altan-Bonnet, Armita Nourmohammad

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design principles of the cytotoxic CD8Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Obinna A UkoguDepartment of Applied Mathematics, University of Washington, Seattle, WA 98105.ORCID 0000-0002-6170-9035
Zachary MontagueDepartment of Physics, University of Washington, Seattle, WA 98195.
Grégoire Altan-BonnetImmunodynamics Group, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.ORCID 0000-0002-7283-3162
Armita NourmohammadDepartment of Applied Mathematics, University of Washington, Seattle, WA 98105.ORCID 0000-0002-6245-3553

Funding

Learning a molecular shape space for the adaptive immune systemR35GM142795 · NIGMS · UNIVERSITY OF WASHINGTON · PI NOURMOHAMMAD, ARMITA · 2021 to 2025
$1.8M
Dynamics of viral infectionZIABC012007 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALTAN-BONNET, GRÉGOIRE · 2020 to 2025
$1.6M
HHS | NIH | National Cancer Institute (NCI) ZIA BC 012007National Science Foundation (NSF) 2045054NIGMS NIH HHS R35 GM142795
6 · The paper itself

Abstract

Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T cell responses emerge from cellular decision-making remain elusive. Here, we recast the T cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation, and death are regulated through antigenic, pro- and anti-inflammatory cues. By exploring a broad class of feedback-controller designs as potential immune programs, we demonstrate how the speed and magnitude of T cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T cell responses by hierarchical sensitivity to different immune signals. Notably, we find the designs that balance harm from acute infections and autoimmunity produce immune responses consistent with the experimentally observed patterns of T cell effector expansion in mice. Extending our model to immune-based T cell therapies for cancer tumors, we quantify the trade-off between the affinity for tumor antigens ("quality") and the abundance ("quantity") of infused T cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T cells. Our findings offer a unified control-logic for cytotoxic T cell responses and point to specific regulatory programs that can be engineered for more robust T cell therapies.

Indexed as

CD8-Positive T-LymphocytesModels, ImmunologicalT-Lymphocytes, CytotoxicAnimalsHumansLymphocyte ActivationMicecell-fate decision-makingfeedback controlPareto optimalityT cells

Identifiers

PMID42030147
PMCPMC13123835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.